Combining previous findings of alterations in immune checkpoint factors in AML, we for the first time established a prognostic model based on BATF, EGR1, PD-1, PD-L1, and TIM-3 that effectively predicts survival outcomes for both AML patients and those receiving allo-HSCT. This evidence concerns the gene BATF and acute myeloid leukemia.